{"id":"W3169849224","doi":"10.1016/s1470-2045(21)00216-3","title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eisai; Array BioPharma; Clovis Oncology; Roche; Mersana Therapeutics; Novartis; Merck KGaA; Merck; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Javelin; Ovarian cancer; Avelumab; Medicine; Refractory (planetary science); Chemotherapy; Open label; Oncology; Internal medicine; Cancer; Clinical trial; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001202018,0.001237333,0.002552269,0.0004132803,0.0002899703,0.0009954689,0.0007260093,0.001342629,0.006327546],"category_scores_gemma":[0.001387456,0.000588307,0.001674086,0.0004306757,0.001036878,0.001186102,0.0003410514,0.002856123,0.001014292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005917924,"about_ca_system_score_gemma":0.0006481335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008652353,"about_ca_topic_score_gemma":0.002206795,"domain_scores_codex":[0.9996368,0.0001929859,0.00001742002,0.00006127322,0.00002515377,0.00006646174],"domain_scores_gemma":[0.9993243,0.0002596377,0.0001257631,0.00005105353,0.00002555115,0.0002137227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9666677,0.006430103,0.0004006393,0.0005937877,0.0007754713,0.00002537678,0.00005506372,0.0004417641,0.00279091,0.0001429562,0.000866207,0.02081011],"study_design_scores_gemma":[0.9243148,0.0723602,0.001376556,0.00002799371,0.0003497831,0.00003025964,0.00002546206,0.0004399921,0.0003022539,0.000178659,0.0005768172,0.00001719897],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891243,0.00448563,0.0006453345,0.0006115057,0.0004797438,0.001378594,0.0009604449,0.0001372236,0.0021773],"genre_scores_gemma":[0.9864523,0.0036235,0.00138196,0.0008578201,0.0003250547,0.001644799,0.0009307336,0.00004361104,0.004740279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006327546,"threshold_uncertainty_score":0.02116776,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09341405805658175,"score_gpt":0.4002533787875807,"score_spread":0.3068393207309989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}